I would bet if this is very successful on patients who meet the criteria for inclusion in this trial-then neurosurgeons will "throw caution to the wind" and start using it in patients who don't fit the typical criteria--because patients and their families will be clamoring for it-and who could blame them if the alternative is long term (if not permanent) disability
management said any "partnership" agreement would be 3-6 weeks after announcement of FDA approval--so anywhere between-July 18 to August 8
Points that are all well taken
--what do you think would be a "reasonable" pps if partnership vs complete takeover? I doubt MNKD would agree to a complete takeover--the technosphere technology will be a "cash cow" for the company for years---but if Mr. Mann agrees to a takeover this potential had better be factored into the final price
MNKD once traded at $20 pps without any FDA approval (then fell after the 2nd CRL letter)---why would it be in "low teens" after acceptance--nonsense-Mr. Mann would have to be "demented" to settle for such a "low ball" offer even if it was just a partnership
Are you kidding me?? MNKD was $20 pps prior to its second CRL letter and that was with no approval--why would Mr. Mann settle for "13-14" on a buyout??? I DON'T THINK SO!!
why is Barrons suggesting to "take profits" now?? just an attempt to scare Longs into getting rid of at least some of their shares so they can be bought up before the partnership/buyout announcement at a cheaper price? I thought Barrons would be above something like this?
"InVivo Therapeutics Holdings Corp. (NVIV) today announced that the role of Christopher McNulty has been expanded to include investor relations and corporate communications"
Hopefully this means more "transparency" and updates as to what is going on--something that has been greatly lacking since Mr. Perrin took over from Mr. Astrue-in fact I can't remember one time that Mr. Perrin directly addressed shareholders in a news release etc.
Clovis is $40 pps-although 1 year target is $80 pps---do you see anything else that is more affordable that has MNKD's potential? Thks
That will depend on if there are at least some positive results from one of these clinical trial sites---how can they make any kind of deal if there are no positive results-otherwise they are just selling an idea not a workable product
What exactly is $12 pps as a buyout??? Mr. Mann went throught 2 CRL letters, $900 million of his own money to keep this company and Afrezza going--and all he'll get in a buyout is $12 pps??? (even $25 pps is a joke)--no way---the Technosphere Technology alone is worth +$50 based on its far reaching potential
Sentiment: Strong Buy
I've been a physician (hospital internal medicine specialist) for 20 years--a large part of my practise deals with type 2 diabetics and the biggest problem I've had managing their diabetes is non compliance when they need to use insulin--the vast majority HATE needles which makes compliance difficult-hence all the nasty complications that subsequently insue due to poor glycemic control---I've had a steady stream of patients approach me about when they will be able to get Afrezza--most I'm sure will be calling me this upcoming week to find out when it will be available--as far as the insurance coverage---what do think the insurance companies will think about an insulin preparation that will ultimately save them billions in the cost of the treatment of complications (i.e dialysis, blindness, peripheral neuropathy etc etc)--your comments make absolutely no sense to me??
Mr. Mann has already mentioned that he could see the day when migraines could be treated with analgesics delivered with this technosphere med delivery method--no more waiting for a "pill" to dissolve in the digestive tract to then be absorbed to bring relief
FDA approval of Afrezza completely establishes the Technosphere platform to be valid for moving into the pain management market and other markets described previously by the company directors. In fact, it has been recently reported that Mr. Mann was quoted as saying that MannKind has been in a pre-clinical phase of entering the pain management market. I would bet a quick announcement of Technosphere entering clinical trials for pain management, since it is a global $60 billion market in itself.
And I'll bet there will be many new Type 2 diabetics who smoke/have COPD who are going to find some way to get their hands on Afrezza-to avoid needles if possible--I'll bet this "spasm" issue is not going to stop them
I'll bet many diabetic COPD/smokers will find some way to get hold of Afrezza--especially newly diagnosed Type 2 patients who abhor the thought of using a needle---ultimately this "spasm" concern will not be as big a deal as thought-and besides "peabrain" the size of the patient cohort who will benefit from Afrezza is far larger than the group the FDA label is excluding
Not only was Afrezza approved today but the FDA has essentially validated MNKD's proprietary technosphere technology to carry the insulin---that being the case you can be absolutely certain that other companies are going to be approaching MNKD about using this method to attach other drugs for inhalation administration--i.e migraine headache analgesics etc.
Now lets see how soon the partnership is announced--my bet is the deal is signed and will be announced next week!!
"'Anyone who doubts the science or potential of this company now is simply a troublemaker"
That pretty much describes that disgusting troll "imamisanthrope" who I'm sure will soon be crawling out of his hole like he always does when good news is impending
what about a shareholder "uprising" against Perrin and a vote to bring Micheal Astrue back??--I'm very angry that in the time Perrin has been CEO there has not been one attempt to address the shareholders--I don't think he give a "rat's #$%$" about the shareholders---after all the false bravado of Reynolds he owes it to the shareholders to be more upfront about what is going on
sure I originally bought in because of the promise of the scaffold--but it was reassuring to know this company had other things in the "pipeline"--now with the hydrogel "scuttled" (although Micheal Astrue said in his final letter that NVIV was in negotiation with companies interested in using the hydrogel) they have put this company in a very very precarious position if the scaffold doesn't work. And if it doesn't you can be sure that the FDA will likely not allow this program to go on if at all